中科新生命聚焦在生命大健康产业链建设，布局产业链上下游的科技服务、医药研发、临床检测三大业务板块。公司已建立5700m2的上海研发中心、5000m2的义乌产能基地和2000m2的泰州医学检验中心，同步布局全国各地的销售分中心，2021年即将完成1100 m2 cGMP小试平台建设。
作为大健康产业链上游创新引擎的科技服务事业部，已建立起以蛋白质组、修饰组、代谢组、脂质组、基因组、转录组为核心的创新型多组学平台，为生命科学的发展提供坚实、专业、前沿的基础性研究。
医药研发的突破引领产业的未来，生物医药事业部建立大分子药物临床前药学研究服务，贯穿生物药研发管线的各个环节，致力于帮助客户解决新药研发中的疑难杂症。
精准医疗，大健康产业重要的发展方向。临床诊断事业部全国布局、建设独立医学检验所，实现基础研究到临床应用的完美转化，为人类的生命健康保驾护航。
Shanghai Applied Protein Technology (APT), established in 2004, focuses on healthcare and precision medicine industry, and has three business units including academic service, biopharmaceutical service and clinical service.
With vigorous development in the human health field, APT has built 5700m2 of R&D center in Shanghai, 5000m2 of production site in Yiwu, Zhejiang and 2000m2 of clinical service in Taizhou, Jiangsu, with sales offices across the country.
As the upstream innovation engine of health industry, Academic Service BU has established an innovative multi-proteomics platform including proteomics, post-translational modification, metabolomics, lipidomics, genomics and transcriptomics, providing robust, professional and cutting-edge basic academic research service for advancing the development of life science.
R&D breakthrough leads the future of pharmaceutical industry. Biopharma Service BU offers preclinical pharmacy research services for biopharmaceutical companies’ R&D and new drug application, covering the whole line of biopharmaceutical R & D.
Precision medicine is an important development direction of the health industry. Clinical Service BU of APT aims at developing advanced clinical diagnostic techniques based on mass spectrometry technology, and is establishing independent medical laboratories across the country, providing services to facilitate the translation from basic researches to clinical applications, and protecting human life and health.